Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Certara Inc | CERT | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 17.30 | 03:05:20 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 17.30 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 11.81 - 24.6064 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 17.30 | USD |
Certara Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2.77B | 159.86M | - | 354.34M | -55.36M | -0.35 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Certara News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CERT Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 16.21 | 17.915 | 16.00 | 16.94 | 428,843 | 1.09 | 6.72% |
| 1 Month | 16.86 | 19.1792 | 15.78 | 17.30 | 485,085 | 0.44 | 2.61% |
| 3 Months | 16.37 | 19.8702 | 15.78 | 17.69 | 527,127 | 0.93 | 5.68% |
| 6 Months | 12.57 | 19.8702 | 12.09 | 16.47 | 577,688 | 4.73 | 37.63% |
| 1 Year | 24.44 | 24.6064 | 11.81 | 17.22 | 753,084 | -7.14 | -29.21% |
| 3 Years | 32.16 | 45.48 | 10.60 | 21.79 | 803,029 | -14.86 | -46.21% |
| 5 Years | 35.01 | 45.48 | 10.60 | 22.85 | 792,606 | -17.71 | -50.59% |
Certara Description
| Certara Inc accelerate medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trial, accelerate regulatory approval and increase patient access to medicines. The group has a business presence in the United States, EMEA and other regions, of which a majority of revenue is derived from the United States. |
